银杏叶提取物治疗大鼠肝纤维化的机制研究
|
摘要
肝纤维化不论何种病因，细胞外基质(exacellular matrix，ECM)增加是其特征，表现为ECM数量增加和／或成分改变。其发展的细胞和分子机制的阐明，为这一疾病的防治提供了依据。几乎所有的临床和动物实验研究均提示纤维化的发生发展与氧化应激(oxidative stress，OS)、氧自由基损伤、脂质过氧化等有关。研究证实，抗氧化剂可通过抑制肝星状细胞(hepatic stellate cell，HSC)活化和增殖，减少ECM的合成，从而起到预防和减轻肝纤维化的作用。
现代研究发现，银杏叶所含主要成分银杏黄酮甙能有效地清除体内有毒过氧自由基的作用，银杏苦内酯因其有高度专属性抗血小板活化因子(PAE)的作用而引起国际医学界的关注。近年来，欧洲专题报道银杏叶中存在活性成分Bioparyl(一种抗氧化剂)，可调节核糖核酸酶的活性，防止／逆转各组织纤维变性，因此推测银杏叶有抗氧化应激作用，可促进肝纤维化的恢复。
迄今为止对银杏叶提取物抗肝纤维化的作用及其机制缺乏系统深入的研究，国内外尚无银杏叶提取物治疗实验性肝纤维化的研究报道。为此，我们进行实验研究，利用四氯化碳诱导大鼠肝纤维化模型，采用银杏叶提取物对其进行治疗，观察银杏叶提取物对肝纤维化大鼠一般情况及肝功能指标、肝脏组织病理学的影响；对肝组织中氧化指标MDA的含量，SOD、GSH-PX的活性的影响；对肝纤维化大鼠细胞因子TGF-β1和Activill A表达的影响；对肝纤维化大鼠肝星状细胞活化及肝细胞凋亡的影响；以及对肝纤维化大鼠肝组织MMP-1及TIMP-1基因表达的影响。希望通过本组实验研究银杏叶提取物对大鼠肝纤维化的治疗作用，并从分子水平、细胞水平以及氧化应激、细胞外基质降解方面探讨银杏叶提取物治疗大鼠肝纤维化的作用机制，为临床合理应用银杏叶制剂提供参考依据。整个实验共分为6个部分：
1 银杏叶提取物对肝纤维化大鼠一般情况及肝功能指标的影响
目的：利用银杏叶提取物对肝纤维化大鼠进行治疗，观察治疗过程中肝纤维化大鼠的一般情况及其血清肝功能指标的变化。
方法：48只雄性SD大鼠被随机分为四组：正常组、肝纤维化模型组、秋水仙碱
Hepatic fibrosis is predominantly characterized by excessive accumulation of extracellular matrix (ECM) components in the liver, caused by an imbalance between synthesis and degradation of ECM. Up to now, no effective treatment of hepatic fibrosis is available for clinical use, in particular, no method for enhancing; degradation and resolution of these deposited ECM. and reversing hepatic fibrosis. Ginkgo Biloba extract(EGB) is an extract from green leaves of the Ginkgo biloba tree. EGB has been shown to have a SOD-like activity and hydroxyl radical scavening activity. Accordingly, we guess EGB can inhibit oxidative stress and hasten recovery of hepatic fibrosis.
So far, there is no systemic research in treating hepatic fibrosis by Ginkgo biloba extract(EGB). Therefore, we use EGB treating CCl_4-induced hepatic fibrosis, and investigate the effect of general state of health, indication of liver function and histopathology on hepatic fibrosis's rat. Also ,we explore the effect of the oxidative indication such as MDA, SOD and GSH-Px, the express of TGF-β_1 and Activin A , the activation of HSC, the apoptosis of liver cell, and the gene express of MMP-1 and TIMP-1. From the experiment, we will investigate the therapia effect of EGB on fibrosis's rat, and explore the treated mechanism from oxidative stress, molecular level, cellular level and degradation of ECM by the way. The experiment was divided into six part.
Part 1: The effect of Ginkgo biloba extract on general state of health and indication of liver function in hepatic fibrosis's rat.
Objective: To investigate the change of general state of health and indication of liver in the course of treating hepatic fibrosis's rat. Methods: The study was conducted in 48 adult male SD rats randomized into 4 groups: normal group, model group, treatment group and colchicin group. Except the rats in the normal group, others were inflicted with liver fibrosis by administration of CCL_4 for 8 weeks. Then, the rats of normal group and model group were sacrificed. Blood samples were collected for determination of ALT. AST. AKP and ALB. Those rats in the treatment
现代研究发现，银杏叶所含主要成分银杏黄酮甙能有效地清除体内有毒过氧自由基的作用，银杏苦内酯因其有高度专属性抗血小板活化因子(PAE)的作用而引起国际医学界的关注。近年来，欧洲专题报道银杏叶中存在活性成分Bioparyl(一种抗氧化剂)，可调节核糖核酸酶的活性，防止／逆转各组织纤维变性，因此推测银杏叶有抗氧化应激作用，可促进肝纤维化的恢复。
迄今为止对银杏叶提取物抗肝纤维化的作用及其机制缺乏系统深入的研究，国内外尚无银杏叶提取物治疗实验性肝纤维化的研究报道。为此，我们进行实验研究，利用四氯化碳诱导大鼠肝纤维化模型，采用银杏叶提取物对其进行治疗，观察银杏叶提取物对肝纤维化大鼠一般情况及肝功能指标、肝脏组织病理学的影响；对肝组织中氧化指标MDA的含量，SOD、GSH-PX的活性的影响；对肝纤维化大鼠细胞因子TGF-β1和Activill A表达的影响；对肝纤维化大鼠肝星状细胞活化及肝细胞凋亡的影响；以及对肝纤维化大鼠肝组织MMP-1及TIMP-1基因表达的影响。希望通过本组实验研究银杏叶提取物对大鼠肝纤维化的治疗作用，并从分子水平、细胞水平以及氧化应激、细胞外基质降解方面探讨银杏叶提取物治疗大鼠肝纤维化的作用机制，为临床合理应用银杏叶制剂提供参考依据。整个实验共分为6个部分：
1 银杏叶提取物对肝纤维化大鼠一般情况及肝功能指标的影响
目的：利用银杏叶提取物对肝纤维化大鼠进行治疗，观察治疗过程中肝纤维化大鼠的一般情况及其血清肝功能指标的变化。
方法：48只雄性SD大鼠被随机分为四组：正常组、肝纤维化模型组、秋水仙碱
Hepatic fibrosis is predominantly characterized by excessive accumulation of extracellular matrix (ECM) components in the liver, caused by an imbalance between synthesis and degradation of ECM. Up to now, no effective treatment of hepatic fibrosis is available for clinical use, in particular, no method for enhancing; degradation and resolution of these deposited ECM. and reversing hepatic fibrosis. Ginkgo Biloba extract(EGB) is an extract from green leaves of the Ginkgo biloba tree. EGB has been shown to have a SOD-like activity and hydroxyl radical scavening activity. Accordingly, we guess EGB can inhibit oxidative stress and hasten recovery of hepatic fibrosis.
So far, there is no systemic research in treating hepatic fibrosis by Ginkgo biloba extract(EGB). Therefore, we use EGB treating CCl_4-induced hepatic fibrosis, and investigate the effect of general state of health, indication of liver function and histopathology on hepatic fibrosis's rat. Also ,we explore the effect of the oxidative indication such as MDA, SOD and GSH-Px, the express of TGF-β_1 and Activin A , the activation of HSC, the apoptosis of liver cell, and the gene express of MMP-1 and TIMP-1. From the experiment, we will investigate the therapia effect of EGB on fibrosis's rat, and explore the treated mechanism from oxidative stress, molecular level, cellular level and degradation of ECM by the way. The experiment was divided into six part.
Part 1: The effect of Ginkgo biloba extract on general state of health and indication of liver function in hepatic fibrosis's rat.
Objective: To investigate the change of general state of health and indication of liver in the course of treating hepatic fibrosis's rat. Methods: The study was conducted in 48 adult male SD rats randomized into 4 groups: normal group, model group, treatment group and colchicin group. Except the rats in the normal group, others were inflicted with liver fibrosis by administration of CCL_4 for 8 weeks. Then, the rats of normal group and model group were sacrificed. Blood samples were collected for determination of ALT. AST. AKP and ALB. Those rats in the treatment
引文
1．夏克平，论肝纤维化的中医病证类属及防治，中医研究，2005，18 (6)：7-8
2．张仲景．金匮要略方论[M]．北京：人民卫生出版社，1963，4：35-37．
3．南京中医学院校释．难经校释[M]．北京：人民卫生出版社，1979．123．
4．薛博瑜，顾学兰．肝纤维化的病机认识和辨证论治[J]．南京中医药大学学报(自然科学版)，2001，17 (2)：76-78
5．何浩，张玉亮，严义忠，等．乙型肝炎肝纤维化的中医防治[J]．新中医，2003，35 (4)：75
6．晏军，王熙．王锦之教授治疗肝纤维化经验撷菁[J]．中国医药学刊，2001，19 (5)：410-411
7．苏立稳，杨继先．肝血瘀阻与肝纤维化的关系[J]．承德医学院学报，1999，16 (2)：172-173
8．唐智敏，朱清静，朱起贵．论肝血瘀阻与肝纤维化的关系[J]．中国中医基础医学杂志，1996，2 (3)：14-18
9．卢良威，张永生．活血渗湿法抗肝纤维化探究[J]．浙江中医学院学报，2000，24 (3)：9
10．王晓文．杨培民治疗血吸虫病肝纤维化的经验[J]．湖北中医杂志，2002，24 (2)：13-14
11．史广宇，单书健．当代名医临证精华·肝炎肝硬化专辑[M]．北京：北京中医古籍出版社，1998．325
12．刘绍能，刘为民．从络脉理论探讨肝纤维化证治规律[J]．中国中医药信息杂志，2 003，10 (7)：3-4
13．王建明，王和平，李兴斌．膈下逐瘀汤与柴胡疏肝散对实验性肝纤维化作用研究．中医药学报，1997；25 (6)：49
14．宋家武，李绍白．血府逐瘀汤分解方抗肝纤维化作用的研究．中西医结合肝病杂志，199 5；5 (2)：23
15．陆雄，顾宏图，卢红等．旋复花汤对抗肝纤维化、肝窦毛细血管化逆转作用的实验研究．中国中医药科技 1999；6 (6)：366
16．马跃荣，IchiroSHim jzu，SusumuIto等．小柴胡汤对鼠实验性肝纤维化的影??响．泸州医学院学报，1997；20 (2)：81
17．刘成，刘平．扶正祛瘀方抗肝纤维化作用的研究．中医杂志1994；35(10)602
18．贾继东，王宝恩．中药861合剂对体外培养贮脂细胞Ⅳ型胶原mRNA的影响．中华肝脏病杂志，1996 (4)：142-144
19．马红，王宝恩，董忠等．复方861对大鼠肝星状细胞增殖及胶原合成的影响．中国临床药理学与治病学杂志，1998 (3)：172-175
20．刘永刚，陈厚昌，蒋毅萍．丹参酮ⅡA对四氧化碳致大鼠肝纤维化的实验研究．中药材，2002，25 (1)：31-33
21．陈岳祥，李石，范列英等．丹参单体IH764-3抗肝纤维化作用的实验研究．中华医学杂志，1998，78 (8)：636-637
22．朱金水，朱勋，余小虎等．氧化苦参碱对肝纤维化患者IL-6、IL-8、IL-10水平影响[J]．中国免疫学杂志，2003，19 (3)：191-192
23．盖晓东，王立蓉，杨毅军．氧化苦参碱抗肝纤维化的疗效观察．中国厂矿医学，2003，16 (6)：450-451
24．丁里玉，李春香．抗肝纤维化的中药提取物研究近况及机理．河北中医药学报，2004，19(1)：36-391. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des, 2004, 10 (3) : 261-264
2. Zhang C, Zu J, Shi H, et al. The effect of Ginkgo biloba extract (EGb 761) on hepatic sinusoidal endothelial cells and hepatic microcirculation in CC14 rats. Am J Chin Med, 2004, 32 (1) : 21-31
3. Bahcecioglu IH, et al. Protective effect of Ginkgo biloba extract on CCL4-induced liver damage. Hepatology Research. 1999, 15 (3) : 215-224.
4. Tian X, Tang G, Chen Y. The effects of endothelin-1 and selective endothelin receptor-type A antagonist on human renal interstitial fibroblasts in bitrol. Zhonghua Yi Xue Za Zhi, 2002, 82: 5-9
5. Filimonov PN, Sukhenko TG, Gavrilova NI. Level of serum tumor necrosis factor-alpha and the degree of liver fibrosis in children with chronic viral hepatitis B, C and B, treated with interferon-alpha. Zh Mikrobiol Epidemiol Immunobiol, 2002, 2: 69-72
6. Bwnyon RC, Iredale JP, et al. Is liver reversible? Gut, 2000, 46: 443-446
7．李冬，李兵顺，刘金星．肝纤维化逆转的研究进展．医学综述，2002，8：20-21
8. Ozaras R, Tahan V, Aydin S, et al. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol, 2003, 9: 125-128
9. Yao L, Yao ZM, Yu T. Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats. World J Gastroenterol, 2001, 7: 872-875
10. Gohil K, Packer L. Bioflavonoid-rich botanical extracts show antioxidant and gene regulatory activity. Ann N Y Acad Sci, 2002. 957: 70-77
11. Diamond BJ. Shiflett SC. Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil, 2000, 81: 668-678
12．卢忠明．银杏叶提取物药理作用的生理基础及其临床应用．广西中医学院学报，2001，4：131-133
13. Bridi R. Crossetti FP. Steffen VM. et al. The antioxidant activity of standardized extract of ginkgo biloba (EGb761) in rats. Phytother Res. 2001. 15: 449-45114. Tang Y, Lou F, Wang J, et al. Coumarou flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry, 2001, 58: 1251-1266
15. Wu Z, Smith JV, Paramasivam V, et al. Ginkgo biloba extract increases stress resistance and extends life span of Caenorhabditis elegans. Cell Mol Biol, 2002, 48: 725-731
16. Mazzanti G, Mascellino MT, Battinelli L. Antimicrobial investigation of semipurified fraction of ginkgo biloba leaves. J Ethnopharmacol, 2000, 71: 83-88
17. Schindowski K, Leutner S, Kressmann S, et al. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract. J Neural Transm, 2001, 108: 969-978
18．石玉庆，郑修生．银杏叶提取物总黄酮三大组分浅析．中医研究，2002，13：55-56
19. McKenna DJ, Jones K, Hughes K. Effective, safety, and use of ginkgo biloba in clinical and preclinical applications. Altem Ther Health Med, 2001, 7: 70-86, 88-90
20. Topp S, Knoefel WT, Schutte A, et al. Ginkgo biloba (EGb 761) improves microcirculation after warm ischemia of the rat liver. Transplant Proc. 2001, 33 (1-2) : 979-981.
21. Rimbach G, Wolffram S, Watanabe C, et al. Effect of Ginkgo biloba (EGb 761) on differential gene expression. Pharmacopsychiatry. 2003, 36 Suppl 1: S95-99
22．许庆忠，雷霆雯，马小平．实验性肝纤维化血清白蛋白含量变化．贵阳医学院学报，2002，27：128-129
23. Schuppan D, Ruehl M, Somasundaram R, et al. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis, 2001, 21: 351-372
24. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis; hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 2001, 102: 538-549
25．张力国，胡晋红，蔡榛，等．桑黄抗大鼠肝纤维化与抗脂质过氧化．中成药，2002．24：281-3
26. Yao XX, Tang YW. Yao DM. et al. Effects of Yign Decoction on proliferation and??apoptosis of hepatic stellate cells. World J Gastroenterol, 2002, 8: 511-514
27. Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol, 2003, 9: 1106-1110
28. Yao L, Yao ZM, Yu T. Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats. World J Gastroenterol, 2001, 7: 872-875
29. Ozaras R, Tahan V, Aydin S, et al. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol, 2003, 9: 125-128
30. Yao HW, Li J, Jin Y, et al. Effect ofleflunomide on immunological liver injury in mice. World J Gastroenterol, 2003, 9: 320-323
31. Liu YK, Shen W. Inhibitive effect of cordyceps sinensis on experimental hepatic fibrosis and its possible mechanism. World J Gastroenterol, 2003, 9: 529-533
32. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology, 2002, 33: 379-386
33. Wang LT, Zhang B, Chen JJ. Effect of anti-fibrosis compound on collagen expression of hepatic cells in experimental liver fibrosis of rats. World J Gastroenterol, 2000, 6: 877-880
34. Tang WX, Dan ZL, Yan HM, et al. Experimental study of effect of Ganyanping on fibrosis in rat livers. World J Gastroenterol, 2003, 9: 1292-1295
35. Zhu L, Yang ZC, Li A, et al. Protective effect of early enteral feeding on postburn impairment of liver function and its mechanism in rats. World J Gastroenterol, 2000. 6: 79-83
36. Xu JW, Gong J, Chang XM, et al. Estrogen reduces CCl4-induced liver fibrosis in rats. World J Gastroenterol, 2002. 8: 883-887
37. Yang LQ, Li S J. Cao YF. et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol. 2003, 9: 359-363
38. Kitade Y. Watanabe S, Masaki T, et al. Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a heral medicine. Sho-Saiko-to. Hepatology Res, 2002, 22: 196-20539．杨文卓，曾民德，陆伦根，等．氧化苦参碱预防半乳糖胺诱导的大鼠肝纤维化的实验研究．肝脏，2002，7：2-4
40. Wei HS, Li DG, Lu HM, et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CC14. World J Gastroenterol, 2000, 6: 540-545
41. Lee KS, Lee SJ, Park HJ, et al. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J. 2001; 42 (1) : 1-8
42. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002; 27: 63-68
43. Albanis E, Friedman SL. Hepatic fibrosis: Pathogenesis and principles of therapy. Clin Liver Dis. 2001: 5 (2) : 315-334
44. DeFeudis FV. A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry. 2003, 36 Suppl 1: S2-7.
45. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001; 35: 297-306
46. Wei HS, Li DG, Lu HM, et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CC14. World J Gastroenterol, 2000, 6: 540-545
47. Wang A, Yang X, Wang W, et al. Effect of recombinant human augmenter of liver regeneration on gene expression of tissue inhibitor of metalloproteinase-1 in rat with experimental liver fibrosis. Zhonghua Yi Xue Za Zhi, 2002, 82: 610-612
48. Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine prevents transforming growth factor-beta 1-mediated collagen accumulation in cultured rat hepatic stellate cells. J Lab Clin Med, 2002, 139: 202-210
49. Ozaras R, Tahan V, Aydin S, et al. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol, 2003, 9: 125-128
50．贾乐陶，邓素兰，潘金水．银杏叶提取物保肝降酶作用的实验研究．江苏中医药，2002，23：39-40
51. Wang LT. Zhang B, Chen JJ. Effect of anti-fibrosis compound on collagen expression of hepatic cells in experimenlal liver fibrosis of rats. World J Gastroenterol, 2000, 6: 877-880
52. Bruck R. Shirin H, Aeed H. et al. Prevention of hepatic cirrhosis in rats by??hydroxyl radical scavengers. J Hepatology, 2001, 35: 457-464
53. Xu JW, Gong J, Chang XM, et al. Effects of estradiol on type Ⅰ, Ⅲ collagens and TGF β_1 in hepatic fibrosis in rats. Shijie Huaren Xiaohua Zazhi 2003; 11: 1185-1188.
54. Ozenirler S, Dincer S, Akyol G, et al. The protective effect of Ginkgo biloba extract on CCl_4-induced hepatic damage. Acta Physiol Hung. 1997-98; 85 (3) : 277-85.
55. Okazaki I, Watanabe T, Hozawa S, et al. Molecular mechanism of reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinase. J Gastroenterol Hepatol. 2000; 15 Suppl; D26-32
56. Carcia Trevijano ER, Iraburu MJ, Fontana L, et al. Transforming growth factor betal induces the expression of alpha(r) procollagen mRNA by a hydrogen peroxide C/EBP beta dependent mechanism in rat hepatic stellate cells. Hepatology. 1999; 29 (3) : 960-970.
57. Yao XX, Tang YW, Yao DM, et al. Effects of Yigan Decoction on proliferation and apoptosis of hepatic stellate cells. World J Gastroenterol, 2002, 8: 511-514
58. Wadsworth TL, McDonald TL, Koop DR. Effect of Ginkgo biloba extract(EGb761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor mecrosis factor-α. Biochem Phanna, 2001, 62: 963-974
59. Bridi R, Crossetti FP, Steffen VM, et al. The antioxidant activity of standardized extract of ginkgo biloba(EGb761)in rats. Phytother Res, 2001, 15: 449-451
60. Gohil K. Packer L. Bioflavonoid-rich botanical extracts show antioxidant and gene regulatory, activity. Ann N y Acad Sci, 2002, 957: 70-77
61. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol. 2004, 64 (4) : 465-72.
62. Kitade Y. Watanabe S, Masaki T. et al. Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a herbal medicine. Sho-Saiko-to. Hepatology Res, 2002. 22: 196-205
63. Friedman SL. Molecular regulation and hepatic fibrosis, an integrate cellular??response to tissue injure. J Biol Chem2000; 275: 2247-2250.
64. Hock JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002; 27: 63-68.
65. Albanis E, Friedman SL. Hepatic fibrosis: Pathogenesis and priciples of therapy. Clin Liver Dis, 2001, 5 (2) : 315-334.
66. Lamireau T, Desmouliere A, Bioulac-Sage P, et al. Machanisam of hepatic fibrogenesis. Arch Pediatr, 2002, 9 (4) : 392-405.
67. Kanzler S, Lohse AW, Keil A, et al. TGF-beta 1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol, 1999, 27 (4) : 1059-1068.
68. Wang XZ, Zhang LJ, Li D, et al. Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4. World J Gastroenterol, 2003, 9: 539-543.
69. Friedman SL. Molecular regulation of hepatic fibrosis, an integrate cellular response to tissue injure. J Biol Chem. 2000, 275: 2247-2250.
70. Teresa K, Woodruff. Regulation of cell and system function by Activin. Biochemical Pharmacology. 1998, 55: 953-963.
71. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120: 1784-1800
72. Gentilini A, Feliers D, Pinzani M, et al. Characterization and regulation of insulin like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol. 1998; 174 (2) : 240-250.
73. Roberts RA, James NH, Cosulich SC. Therole of protein kinase mitogen activated protein kinase in epidermal growth factor and tumor necrosis factor alpha mediated rat hepatocyte survival and apoptosis, Hepatology. 2000; 31 (2) : 420-427.
74. Kim KY, Choi T, Kim SS. Progression of hepatic stellate cell activation is associated with the level of oxidative stress rather than cytokines during CCl_4-induced fibrogenesis. Mol Cell. 2000; 10 (3) : 289-300
75. Lee KS, Lee SJ, Park HJ. et al. Oxidative stress effect on the activation of hepatic??stellate cells. Yonsei Med J. 2001; 42 (1) : 1-8
76. Rockey DC. The cell and molecular biology of hepatic fibrogensis: clinical and therapeutic implications. Clin Liver Dis. 2000; 4: 319-355
77. Schwabe RF, Schnabl B, Kweon YO, et al. CD40 activates NF-kappa B and c-JunN-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001; 166 (11) : 6812-6819
78. De-Blesser PJ, Niki T, Rogiers V, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-557
79. Greenwel P, Dominguez-Rosales JA, Mavi G, et al. Hydrogen peroxide: a link between acetaldehyde-elicited alphal(Ⅰ) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology. 2000; 31: 109-116
80. Sato M, Kakubari M, Kawamura M, et al. The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide. Biochem Pharmacol. 2000; 59 (6) : 681-90
81. Baroni GS, Pastorelli A, Manzin A, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver. 1999 Jun; 19 (3) : 212-219.
82. Murawaki Y, Nishimura Y, lkuta Y, et al. Plasma transforming growth factor betal concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1998; 13 (7): 680-684.
83．甘雪婷，白宪光．细胞因子TGF-β与慢性肝病肝纤维化的关系．医学信息．2002；15(7)：466-468
84. Albanis E. Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis. 2001; 5: 315-334
85. Luisi S, Florio P, Reis FM. et al. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol. 2001, 14 5(3) : 225-236.
86. Naumnik B, Borawski J. Mysliwiec M. Activin A-follistatin: new cytokines, new perspectives. Pol Arch Med Wewn. 2003. 109 (4) : 431-435.
87. Patella S, Phillips DJ, Kretser DM, et al. Characterization of serum activin A and??0follistation and their relation to virological and histological determination in chronic virtual hepatitis. J Hepatol 2001;34:576-583.
88. Pirisi M, Fabris C, Luisi S, et al. Evaluation of circulating activinA as a serum marker of hepatocelluar carcinoma. Cancer Detect Prev 2000, 24:150-155.
89. Wagner K, Peters M, Scholz A, et al. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology. 2004,126(7):1828-1843.
90. Huang X, Li DG, Wang ZR,et al. Expression changes of activin A in the development of hepatic fibrosis. World J Gastroenterol. 2001,7(l):37-41.
91. Sugiyama M, Ichida T, Sato T, et al. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology, 1998;114:550-558.
92. Gold EJ, Francis RJ, Zimmermann A, et al. Changes in activin and activin receptor subunit expression in rat liver during the development of CCM-induced cirrhosis. Mol Cell Endocrinol. 2003 , 28:201 (1-2): 143 -153.
93. Date M, Matsuzaki K, Matsushita M, et al. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol. 2000,32(2):251-260.
94. Hughes RD. Evans LW. Activin A and follistatin in acute liver failure. Eur J Gastroenterol Hepatol. 2003,15(2):127-131
95. Ohnishi N, Miyata T, Ohnishi H, et al. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut. 2003,52(10): 1487-1493.
96. Wada W, Kuwano H, Hasegawa Y, et al. The dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology. 2004,145(6): 2753-2759..
97. Gold EJ. Francis RJ. Zimmermann A, et al. Changes in activin and activin receptor subunit expression in rat liver during the development of CCM-induced cirrhosis. Mol Cell Endocrinol. 2003 ,28:201(1-2): 143-153.
98. Yasuda H, Mine T, Shibata H, et al. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest. 1993.92(3): 1491-1496.99. Hully JR, Chang L, Schwall RH, et al. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology. 1994,20(4 Pt 1):854-862.
100. Kanamaru C, Yasuda H, Fujita T. Involvement of Smad proteins in TGF-beta and activin A-induced apoptosis and growth inhibition of liver cells. Hepatol Res. 2002,23(3):211-219.
101. Ichikawa T, Zhang YQ, Kogure K, et al. Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver. Hepatology. 2001;34(5):918-925.
102. Gold EJ, Zhang X, Wheatley AM, et al. betaA- and betaC-activin, follistatin, activin receptor mRNA and betaC-activin peptide expression during rat liver regeneration. J Mol Endocrinol. 2005,34(2):505-515.
103. Wada W, Kuwano H, Hasegawa Y, et al. The dependence of transfonning growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology. 2004,145(6):2753-2759.
104. Ohnishi N, Miyata T, Ohnishi H, et al. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut. 2003,52(10): 1487-1493.
105. Breitkopf K, Lahme B, Tag CG, et al. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001; 33: 387-396
106. Britton RS, Bacon BR. lntracellular signsling pathways in stellate cell activation. lsr Med Assone J ,2000,2(sUPPL):7480.
107. Tanigucbi H, Kato N, Otsuka M. et al. Hepatitis C virus core protein upregulate transforming growth factor-beta 1 transcription. J Med Virol, 2004, 72(1): 52-59.
108. Yang C, Zeisberg M. Mosterman B, et al. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology, 2003.24(2):147-159.
109. Wang JY, Zhang QS, Guo JS. et al. Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats.??World J Gastroenterol, 2001, 7:115-119
110. Gagliano N, Arosio B, Grizzi F, et al. Reduced collagenolytic activity of MMPs and development of liver fibrosis in the aging rat. Machan Aging Develop, 2002, 123:413-425
111. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects of matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem, 2002, 277: 11069-11076
112. Bruck R, Shirin H, Aeed H, et al. Prevention of hepatic cirrhosis in rats by hydroxyl radical scavengers. J Hepatol, 2001, 35: 457-464
113. Parola M, Robine C. Oxidative stress-related molecules and liver fibrosis. J Hepatol, 2001, 35:297-306
114. Reeves HL, Dack CL, Peak M, et al. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol, 2000; 32:465-472
115. Chen W, Woodruff TK, Mayo KE. Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins. Endocrinology, 2000, 141: 1263-1272
116. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002; 27: 63-68.
117. Aibanis E, Friedman SL. Hepatic fibrosis: Pathogenesis and priciples of therapy. Clin Liver Dis, 20015(2):315-334.
118．王爱民，杨晓明，王文犀，等．重组人肝再生增强因子抑制实验性肝纤维化MMP-2基因表达．中华消化杂志，2002，22：29229-4
119．谢彦华，李里，王立娥，等．MMP-2、-9与肝纤维化．临床肝胆病杂志，2002，11：82-84
120. Gardi C. Arezzini B, Fortino V, et al. Effect of flee iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells. Biochem Pharmacol. 2002, 64: 1139-1145
121. Boeker KH. Haberkorn Cl, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis??C. Clin China Acta, 2002, 316:71-81
122. Okazaki I, Watanabe T, Hozawa S, et al. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases. J Gastroenterology Hepatology, 2000, 15 (suppl): D26-D32
123. Michael JR Fibrogenesis Ⅱ. Metalloproteinases and their inhibitors in liver fibrosis. AJP-Gastrointestinal Liver Physiology, 2000, 279: G245-G249,
124. Guo MZ, Li XS, Xu HR, et al. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin, 2002, 23:739-744
125. Wang JY, Guo JS, Yang CQ. Expression of exogenous rat collagenase in vitro and in a rat model of liver fibrosis. World J Gastroenterol, 2002, 8:901-907
126. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis; hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest, 2001, 102:538-549
127. Ninomiya T, Yoon S, Nagano H, et al. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients, Intervirology, 2001, 44: 227-231
128. Liu P, Hu YY, Liu C, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol, 2002, 8: 679-685
129. Murply HR, lssa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by TIMP-2 is mediated via effects on MMP inhibition: implications for reversibility of live fibrosis. J Biol Chem, 2002, 277: 11069-11076
130. Weng HL. Cai WM, Liu RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis. World J Gastroenterol. 2001, 7:42-48
131. Yoshiji H, Kuriyama S, Miyamoto Y. et a1. TIMP-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology, 2000, 32: 1248-1254
132．杨长青，胡国龄，谭千德，等．实验性肝纤维化时MMP-1、TIMP-1的表达与Ⅰ、Ⅲ型肢原含量变化的关系．临床肝胆病杂志，2000，16：222-224
133. Nie QH. Cheng YQ, Xie YM. et al. Methodologic research on TIMP-1. TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance. World J Gastroenterol, 2002. 8: 282-287134. Nie QH, Cheng YQ, Xie YM, et al. Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol, 2001, 7:363-369
135. Liu WB, Yang CQ, Jiang W, et al. Inhibition on the production of collagen type Ⅰ, Ⅲ of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid. World J Gastroenterol, 2003, 9:316-319
136. Liu HL, Li XH, Wang DY, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver. World J Gastroenterol, 2000, 6:881-884
137. Guo MZ, Li XS, Xu HR, et al. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin, 2002, 23:739-744
138. Williams EJ, Benyon RC, Trim N, et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut, 2001,49:577-5831．程明亮，杨长青．肝纤维化的基础研究及临床．北京，人民卫生出版社，2002：2～20
2．梁扩寰，李绍白．肝脏病学．北京，人民卫生出版社，1995
3. Ozenirler S, Dincer S, Akyol G. et al. The protective effect on Ginko binka extract on CCL~4-induced hepatic damage. Area Physiol Hung. 1997-89;85(3):277-85
4. Czaja MJ, Weiner FR. Flanders KC, et al. In vitro and in vivo association of Teansforming Growth Factor-1 with hepatic fibrosis. J Cell Biology. 1989. 108(6): 2477-2482
5．宋仕玲．细胞因子及其网络对肝纤维化的作用．人民军医，200 3，46(10)：606-609
6. ]Lau AL. Kumar TR, Nishimor K. et al. Activin beta C and beta E genes are not??essential for mouse liver growth differentiation, and regeneration. Mo; Cell Biol, 2000,20:6127-6137
7. Date M, Matsuzaki K, Matsushita M, et al. Differential regulation of activinA for hepaticyte growth and fibronectin synthesis in rat liver injuty. J H epatol, 2000.32:251-260
8. Patella S, Phillips DJ, Kretser DM, et al. Characterixation of serum activinA and follistation and their relation to virological and histological determination in chronic virtual hepatitis. J Hepatol 2001;34:576-583
9. Harada K, Shintani Y, Wakatsuki M, et al. Serum immunoreactive activin A in normal subjects and patients with various diseases. J Cli Endoctino Metab 1996;81:2125-2130
10. Pisisi M, Fabris C, Luisi S, et al. Evaluation of circulating activinA as a serum marker of heptocellular carcinoma. Cancer Detect Prev 2000;24:150-155
11．黄新，李定国．激活素及相关肽与肝脏疾病研究进展．中华肝脏病杂志，2000，8(5)：319-320
12. Yasuda H, Mine T, Shibata H, et al. Activin A: an autocrine in hibitor of initiation of DNA synthesis in rat hepatocyres[J], J. Clin Invest. 1993,92(9):1491-1496
13. Schwall RH, Robbins K, Jardieu P, et al. Activin A induces cell drath in hepatocytes invivoand in vitro [J]. Hepatology, 1993,18(2):347-356
14. Hully JR, Chang L, Schwall RH, et al, Induction of apoptosis in the murine liver recombinant human activin A[J]. Hepatology, 1994,20(4):854-862
15. Zhang YQ, Kanzaoi M, Mashima H. et al. Norepinephrine reverses the effects of activin A on DNA synthesis and apoptosis in cultured rat hepatocytes[J]. Hepatology, 1996, 23(2):288-293.
16. Gaca MD. Pickering JA. Arthur MJ et al. Human and rat hepatjc stellate cells produce ste m cell factor: a possible mechanis m for mast sell recruit in liver fibrosis. J Hepatol,1999,30(5):850
17．卢良威．肝纤维化的治疗研究．浙江中医学院学报，2001，25(2)：25-27
18. Riveta CA. Bradford BC, Hunt KJ. et al. [J]. Am J Physol Gastrointest Liver Physiol. 2001Jul. 281(1): G 200-G20719. Kim KY, Choi T, Kim SS. [J]. Mol Cells, 2000 Jun 30, 10(3): 289-300
20. Albanis E, Friedman SL. [J]. Clin Liver Dis, 2001, 5(2): 315-34
21. Zhu N, Ramirez LM, Lee RL, et al. [J].J Immunol 2002; 168:744-754
22. Lee KS, Lee SJ, Park HJ, et al. [J]. Yonsei Mde J, 2001 Feb, 42(1): 1-8
23. Rockey DC, Fouassier L, Chung JJ, et al. [J]. Hepatology, 1998,27:472 480.
24. Hellerbrand C, Stefanovic B, Ciordano F. [J]. J Hepatol, 1999, 30(1): 77-87
25. Okuno M, Akita K, Moriwake H, et al. [J]. Gastoenterology, 2001 Jun, 120(7): 784-800
26. George J, Roulot D, Koteliansky VE, et al. [J].Proc Natl Acad Sci USA, 1999 Oct 26,96(22): 19-24
27. Nakathura T, Sakata R, Ueno T, et al. [J]. Hepatology, 2000Aug, 32(2): 247-255
28. Swaisgood CM, French EL, Noga C, et al .[J]. Am J Pathol, 2000,157:177-187
29. Sato M. Kawanmura M, Kakubari M, et al. [J]. Biochem Pharmacol, 2000 Mar 15, 59(6): 681-90
30. Bruck R, Genina O, Aeed H, et al. [J]. Hepatology, 2001 Feb, 33(2): 379-86
31. Kimura K. Ando K, Ohnishi H, et al. [J]. Int immunol, 1999, 119:1491-500
32. Okuyama H, Shimahara Y, Kawada N, et al. [J]. J Biol Chem. 2001 Jul 27, 276
33. Gaca MD. Pickering JA. Arthur MJ et al. Human and rat hepatic stellate cells produce ste m cell factor: a possible mechanism for mast sell recruit in liver fibrosis. J Hepalol,1999,30(5):850
34. Okuyama H, Shimahara Y. Kawada N. et al. [J]. J Biol Chem. 2001 Jul 27,276
35. Schwall RH, Robbins K, Jardieu P. et al. Activin A induces cell drath in hepatocytes invivoand in vitro [J]. Hepatology, 1993.18(2):347-356
36. Hully JR, Chang L, Schwall RH. et al. Induction of apoptosis in the murine liver recombinant human activin A [J]. Hepatology. 1994.20 (4): 854-862
37. Zhang YQ, Kanzaoi M. Mashima H. et al. Norepinephrine reverses the effects of activin A on DNA synthesis and apoptosis in cultured rat hepatocytes [J]. Hepatology, 1996,23(2):288-293.1. Bcnyon RC Arther M J[J]. J Pcdiatr Gastrocn-terol Nutr,1998 27(1): 75-85
2. Zhong Z, Froh M, Whcclcr MD, et al [J]. Gene Thcr, 2002,9,183-191
3. Rivcta CA, Bradford BC, Hunt KJ, et al[J] Am J Physol Gastrointest Livcr Physiol, 2001,281(1):G200-G207
4. Kim KY, Choi T, Kim SS[J]. Mol Cells, 2000,10(3): 289-300
5. AlSanis F, Fricdman SL[J]. Clin Livcr Dis ,2001,5 (2): 315-334
6. Zhu N, Ram irEz LM, Lee RL, et al [J]. Jlnmunol,2002,168:744-754
7. Lee KS, Lee SJ, Pack H J, et al[J]. Yonsci Mcdl, 2001,42(1): 1-8
8. Rockey DC, Fouassicr L, Chung JJ, et al[J], Hepatology,1998, 27:472-480
9. Wu J. EmS IA[J]. J Gastroenterol, 2000,35(9): 665-762
10. Hellerbrand C, Stefanovic B, Ciordano F. [J]. J Hepatol, 1999, 30(1): 77-87
11. Benedetti A, Di Sario, Casini A, et al[J], Gastroenterology; 2001, 120(2): 545-556
12. Okuno M, Akita K, Moriwake H, et al. [J]. Gastoenterology, 2001 Jun, 120(7): 784-800
13. George J, Roulot D, Koteliansky VE, et al. [J].Proc Natl Acad Sci USA, 1999 Oct 26,96(22): 19-24
14. Nakathura T, Sakata R, Ueno T, et al. [J]. Hepatology, 2000Aug, 32(2): 247-255
15. Benedetti A. Di Sario, Casini A, et al[J], Gastroenterology; 2000. 120(2): 545-556
16. Fischer R. Schm itt M, Bodc JG. et al[J], Gastroenterology, 2001. 120(5):1212-1226
17. Swaisgood CM. French EL, Noga C. et al .[J]. Am J Pathol. 2000.157:177-187
18. Sato M, Kawanmura M, Kakubari M. et al. [J]. Biochem Pharmacol. 2000 Mar 15.59(6): 681-90
19. Bruck R. Genina O. Aeed H. et al. [J]. Hepatology. 2001 Feb. 33(2): 379-86
20. [2o] Kimura K. Ando K. Ohnishi H, et al. [J]. Int immunol, 1999. 119:1491-50021. Okuyama H, Shimahara Y, Kawada N, et al. [J]. J Biol Chem, 2001 Jul 27, 276
22. Iredale JP, Bebyon RC, Pickering J. et al[J]. Clin Invest, 1998,102(3): 538-549
23. Re rolle JP, Hertig A, Nguyen G, et al. [J]. Kidney Int, 2000,1841-1850
24. Salgado S, Garcia J, Vera J, et al. [J]. Mol Ther, 2000,2,545-551
25. Park PH, Nan JX, Fark EJ, et al. [J]. Phamacol Toxicol, 2000,87(8): 261-268
26. Kitade Y, Watanabe S, Masaki T, et al, [J], Henatol Res,2002,22(3): 196-205
27. Gohil K, Pacher L, [J]. Ann NY Acad Sci, 2002,95(7):70-77
28. Dem irdag K, Bahcecioglu IH, Ozerean IH, et al. [J]. J Gastroenterol Hepatol, 2004,19(3): 333-338
29. Okazaki T, Watanabe T, Hozawa S, et al.[J].Keil J Med,2001,50(2):58-65
30. Rutao C, Baoen W, Fukui Z, et al. [J]. Chin Med J, 2003,116(3):378-38215．胡义扬，刘平，刘成，等，丹酚酸A抗四氯化碳中毒致大鼠肝损伤和肝纤维化的作用[J]，中国药理学报，1997，18(5)：478-480
16．胡义杨，刘成，刘平，中药有效成分抗肝纤维化研究现状与展望[J]，中草药，1996，27(3)：183-186
17．陈岳祥，李石，范列英等，丹参单体IH764-3抗肝纤维化作用的实验研究，中华医学杂志，1998，8(8)：636-637
18．周俭平，张俊平，刘福党，等，植物黄酮对成纤维细胞增殖和胶原合成的影响[J]，中国药学杂志，1999；34(10)：668-669
19．时昭红，张介眉等，银杏叶提取物对实验性大鼠肝纤维化的逆转作用，中国中西医结合消化杂志，2005，13(3)：148-152
20．曹献英，贲长恩，于世瀛，等．活血化瘀方药抗肝纤维化的形态学研究[J]．武汉大学学报(医学版)，2001，22(1)：37
21．吴亚云，程明亮，陆彤，等．汉丹肝乐对大鼠肝贮脂细胞增殖的影响[J]．贵州医药，2000，24(1)：15
22．杨玲，朱清静，张赤志．抗纤软肝冲剂药物血清对激活肝星状细胞表达Ⅰ型前胶原及TGF-BlmRNA的影响[J]．中国中医基础医学杂志，2001，7(8)：38
23．周小舟，周人桥，漆艳平，等．软肝冲剂对四氯化碳肝硬化大鼠P21mRNA表达的影响[J]．湖南中医学院学报，2002，22(4)：13
24．王灵台，张斌，陈建杰，等．抗纤复方药物血清对肝纤维化大鼠肝细胞生成胶原的影响[J]．中华消化杂志，1999，19(6)：391
25．丁惠国，赵春惠，唐淑珍，等．复方861对肝星状细胞分泌表达内皮素-1蛋白及mRNA的影响[J]．中华肝脏病杂志，2003，11(5)：308
26．刘成海，王晓玲，刘平，等．扶正化瘀319方药物血清对肝星状细胞型胶原及转化生长因子B-1表达的影响[J]．中国中西医结合杂志，1999，19(7)：412
27．郭晓萍，侯允天，李东良，等．柔肝煎冲剂对实验性肝纤维化大鼠血清透明质酸及型前胶原的影响[J]．中医药学报，1996，12(5)：42
28．杨国汉，戴裕光，钟瑜．肝结散抗肝纤维化治疗中PCⅢ、HA、LN的动态变化[J]．北京中医药大学学报，2003，26(1)：4229．许亦斌，季光，曹承楼，等，清肝活血方对肝星状细胞增殖及胶原生成的影响[J]．实用临床医药杂志，2003，7(3)：243
30．朱清静，杨玲．剔毒护肝方对肝星状细胞表达型胶原及TGFβ-1mRNA的影响[J]．中国中医药科技，2002，9(2)：76
31．褚裕义，孙克伟，刘伟士，等．疏肝理脾片抗大鼠免疫性肝纤维化研究[J]．中国中西医结合脾胃杂志，1998，6(2)：98
32．龙爱华，王树槐，陈瑾，等．抑肝健脾复方对肝纤维化大鼠HA、PCⅢ、Ⅳ-C、HyP的影响[J]．中国实验方剂学杂志，2000，6(6)：30
33．田玉岭，刘新钰，张林，等．丹参定位注射抗肝纤维化的临床研究，中西医结合肝病杂志，1998，8(2)：107-8
34．高荣慧．神阙穴敷灸治疗早期肝硬化的临床观察．中国针灸，1996，9：25-6
2．张仲景．金匮要略方论[M]．北京：人民卫生出版社，1963，4：35-37．
3．南京中医学院校释．难经校释[M]．北京：人民卫生出版社，1979．123．
4．薛博瑜，顾学兰．肝纤维化的病机认识和辨证论治[J]．南京中医药大学学报(自然科学版)，2001，17 (2)：76-78
5．何浩，张玉亮，严义忠，等．乙型肝炎肝纤维化的中医防治[J]．新中医，2003，35 (4)：75
6．晏军，王熙．王锦之教授治疗肝纤维化经验撷菁[J]．中国医药学刊，2001，19 (5)：410-411
7．苏立稳，杨继先．肝血瘀阻与肝纤维化的关系[J]．承德医学院学报，1999，16 (2)：172-173
8．唐智敏，朱清静，朱起贵．论肝血瘀阻与肝纤维化的关系[J]．中国中医基础医学杂志，1996，2 (3)：14-18
9．卢良威，张永生．活血渗湿法抗肝纤维化探究[J]．浙江中医学院学报，2000，24 (3)：9
10．王晓文．杨培民治疗血吸虫病肝纤维化的经验[J]．湖北中医杂志，2002，24 (2)：13-14
11．史广宇，单书健．当代名医临证精华·肝炎肝硬化专辑[M]．北京：北京中医古籍出版社，1998．325
12．刘绍能，刘为民．从络脉理论探讨肝纤维化证治规律[J]．中国中医药信息杂志，2 003，10 (7)：3-4
13．王建明，王和平，李兴斌．膈下逐瘀汤与柴胡疏肝散对实验性肝纤维化作用研究．中医药学报，1997；25 (6)：49
14．宋家武，李绍白．血府逐瘀汤分解方抗肝纤维化作用的研究．中西医结合肝病杂志，199 5；5 (2)：23
15．陆雄，顾宏图，卢红等．旋复花汤对抗肝纤维化、肝窦毛细血管化逆转作用的实验研究．中国中医药科技 1999；6 (6)：366
16．马跃荣，IchiroSHim jzu，SusumuIto等．小柴胡汤对鼠实验性肝纤维化的影??响．泸州医学院学报，1997；20 (2)：81
17．刘成，刘平．扶正祛瘀方抗肝纤维化作用的研究．中医杂志1994；35(10)602
18．贾继东，王宝恩．中药861合剂对体外培养贮脂细胞Ⅳ型胶原mRNA的影响．中华肝脏病杂志，1996 (4)：142-144
19．马红，王宝恩，董忠等．复方861对大鼠肝星状细胞增殖及胶原合成的影响．中国临床药理学与治病学杂志，1998 (3)：172-175
20．刘永刚，陈厚昌，蒋毅萍．丹参酮ⅡA对四氧化碳致大鼠肝纤维化的实验研究．中药材，2002，25 (1)：31-33
21．陈岳祥，李石，范列英等．丹参单体IH764-3抗肝纤维化作用的实验研究．中华医学杂志，1998，78 (8)：636-637
22．朱金水，朱勋，余小虎等．氧化苦参碱对肝纤维化患者IL-6、IL-8、IL-10水平影响[J]．中国免疫学杂志，2003，19 (3)：191-192
23．盖晓东，王立蓉，杨毅军．氧化苦参碱抗肝纤维化的疗效观察．中国厂矿医学，2003，16 (6)：450-451
24．丁里玉，李春香．抗肝纤维化的中药提取物研究近况及机理．河北中医药学报，2004，19(1)：36-391. Gertz HJ, Kiefer M. Review about Ginkgo biloba special extract EGb 761 (Ginkgo). Curr Pharm Des, 2004, 10 (3) : 261-264
2. Zhang C, Zu J, Shi H, et al. The effect of Ginkgo biloba extract (EGb 761) on hepatic sinusoidal endothelial cells and hepatic microcirculation in CC14 rats. Am J Chin Med, 2004, 32 (1) : 21-31
3. Bahcecioglu IH, et al. Protective effect of Ginkgo biloba extract on CCL4-induced liver damage. Hepatology Research. 1999, 15 (3) : 215-224.
4. Tian X, Tang G, Chen Y. The effects of endothelin-1 and selective endothelin receptor-type A antagonist on human renal interstitial fibroblasts in bitrol. Zhonghua Yi Xue Za Zhi, 2002, 82: 5-9
5. Filimonov PN, Sukhenko TG, Gavrilova NI. Level of serum tumor necrosis factor-alpha and the degree of liver fibrosis in children with chronic viral hepatitis B, C and B, treated with interferon-alpha. Zh Mikrobiol Epidemiol Immunobiol, 2002, 2: 69-72
6. Bwnyon RC, Iredale JP, et al. Is liver reversible? Gut, 2000, 46: 443-446
7．李冬，李兵顺，刘金星．肝纤维化逆转的研究进展．医学综述，2002，8：20-21
8. Ozaras R, Tahan V, Aydin S, et al. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol, 2003, 9: 125-128
9. Yao L, Yao ZM, Yu T. Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats. World J Gastroenterol, 2001, 7: 872-875
10. Gohil K, Packer L. Bioflavonoid-rich botanical extracts show antioxidant and gene regulatory activity. Ann N Y Acad Sci, 2002. 957: 70-77
11. Diamond BJ. Shiflett SC. Feiwel N, et al. Ginkgo biloba extract: mechanisms and clinical indications. Arch Phys Med Rehabil, 2000, 81: 668-678
12．卢忠明．银杏叶提取物药理作用的生理基础及其临床应用．广西中医学院学报，2001，4：131-133
13. Bridi R. Crossetti FP. Steffen VM. et al. The antioxidant activity of standardized extract of ginkgo biloba (EGb761) in rats. Phytother Res. 2001. 15: 449-45114. Tang Y, Lou F, Wang J, et al. Coumarou flavonol glycosides from the leaves of Ginkgo biloba. Phytochemistry, 2001, 58: 1251-1266
15. Wu Z, Smith JV, Paramasivam V, et al. Ginkgo biloba extract increases stress resistance and extends life span of Caenorhabditis elegans. Cell Mol Biol, 2002, 48: 725-731
16. Mazzanti G, Mascellino MT, Battinelli L. Antimicrobial investigation of semipurified fraction of ginkgo biloba leaves. J Ethnopharmacol, 2000, 71: 83-88
17. Schindowski K, Leutner S, Kressmann S, et al. Age-related increase of oxidative stress-induced apoptosis in mice prevention by Ginkgo biloba extract. J Neural Transm, 2001, 108: 969-978
18．石玉庆，郑修生．银杏叶提取物总黄酮三大组分浅析．中医研究，2002，13：55-56
19. McKenna DJ, Jones K, Hughes K. Effective, safety, and use of ginkgo biloba in clinical and preclinical applications. Altem Ther Health Med, 2001, 7: 70-86, 88-90
20. Topp S, Knoefel WT, Schutte A, et al. Ginkgo biloba (EGb 761) improves microcirculation after warm ischemia of the rat liver. Transplant Proc. 2001, 33 (1-2) : 979-981.
21. Rimbach G, Wolffram S, Watanabe C, et al. Effect of Ginkgo biloba (EGb 761) on differential gene expression. Pharmacopsychiatry. 2003, 36 Suppl 1: S95-99
22．许庆忠，雷霆雯，马小平．实验性肝纤维化血清白蛋白含量变化．贵阳医学院学报，2002，27：128-129
23. Schuppan D, Ruehl M, Somasundaram R, et al. Matrix as a modulator of hepatic fibrogenesis. Semin Liver Dis, 2001, 21: 351-372
24. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis; hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest. 2001, 102: 538-549
25．张力国，胡晋红，蔡榛，等．桑黄抗大鼠肝纤维化与抗脂质过氧化．中成药，2002．24：281-3
26. Yao XX, Tang YW. Yao DM. et al. Effects of Yign Decoction on proliferation and??apoptosis of hepatic stellate cells. World J Gastroenterol, 2002, 8: 511-514
27. Shen L, Fan JG, Shao Y, et al. Prevalence of nonalcoholic fatty liver among administrative officers in Shanghai: an epidemiological survey. World J Gastroenterol, 2003, 9: 1106-1110
28. Yao L, Yao ZM, Yu T. Influence of BOL on hyaluronic acid, laminin and hyperplasia in hepatofibrotic rats. World J Gastroenterol, 2001, 7: 872-875
29. Ozaras R, Tahan V, Aydin S, et al. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol, 2003, 9: 125-128
30. Yao HW, Li J, Jin Y, et al. Effect ofleflunomide on immunological liver injury in mice. World J Gastroenterol, 2003, 9: 320-323
31. Liu YK, Shen W. Inhibitive effect of cordyceps sinensis on experimental hepatic fibrosis and its possible mechanism. World J Gastroenterol, 2003, 9: 529-533
32. Bruck R, Genina O, Aeed H, et al. Halofuginone to prevent and treat thioacetamide-induced liver fibrosis in rats. Hepatology, 2002, 33: 379-386
33. Wang LT, Zhang B, Chen JJ. Effect of anti-fibrosis compound on collagen expression of hepatic cells in experimental liver fibrosis of rats. World J Gastroenterol, 2000, 6: 877-880
34. Tang WX, Dan ZL, Yan HM, et al. Experimental study of effect of Ganyanping on fibrosis in rat livers. World J Gastroenterol, 2003, 9: 1292-1295
35. Zhu L, Yang ZC, Li A, et al. Protective effect of early enteral feeding on postburn impairment of liver function and its mechanism in rats. World J Gastroenterol, 2000. 6: 79-83
36. Xu JW, Gong J, Chang XM, et al. Estrogen reduces CCl4-induced liver fibrosis in rats. World J Gastroenterol, 2002. 8: 883-887
37. Yang LQ, Li S J. Cao YF. et al. Different alterations of cytochrome P450 3A4 isoform and its gene expression in livers of patients with chronic liver diseases. World J Gastroenterol. 2003, 9: 359-363
38. Kitade Y. Watanabe S, Masaki T, et al. Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a heral medicine. Sho-Saiko-to. Hepatology Res, 2002, 22: 196-20539．杨文卓，曾民德，陆伦根，等．氧化苦参碱预防半乳糖胺诱导的大鼠肝纤维化的实验研究．肝脏，2002，7：2-4
40. Wei HS, Li DG, Lu HM, et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CC14. World J Gastroenterol, 2000, 6: 540-545
41. Lee KS, Lee SJ, Park HJ, et al. Oxidative stress effect on the activation of hepatic stellate cells. Yonsei Med J. 2001; 42 (1) : 1-8
42. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002; 27: 63-68
43. Albanis E, Friedman SL. Hepatic fibrosis: Pathogenesis and principles of therapy. Clin Liver Dis. 2001: 5 (2) : 315-334
44. DeFeudis FV. A brief history of EGb 761 and its therapeutic uses. Pharmacopsychiatry. 2003, 36 Suppl 1: S2-7.
45. Parola M, Robino G. Oxidative stress-related molecules and liver fibrosis. J Hepatol. 2001; 35: 297-306
46. Wei HS, Li DG, Lu HM, et al. Effects of AT1 receptor antagonist, losartan, on rat hepatic fibrosis induced by CC14. World J Gastroenterol, 2000, 6: 540-545
47. Wang A, Yang X, Wang W, et al. Effect of recombinant human augmenter of liver regeneration on gene expression of tissue inhibitor of metalloproteinase-1 in rat with experimental liver fibrosis. Zhonghua Yi Xue Za Zhi, 2002, 82: 610-612
48. Cao Q, Mak KM, Lieber CS. Dilinoleoylphosphatidylcholine prevents transforming growth factor-beta 1-mediated collagen accumulation in cultured rat hepatic stellate cells. J Lab Clin Med, 2002, 139: 202-210
49. Ozaras R, Tahan V, Aydin S, et al. N-acetylcysteine attenuates alcohol-induced oxidative stress in the rat. World J Gastroenterol, 2003, 9: 125-128
50．贾乐陶，邓素兰，潘金水．银杏叶提取物保肝降酶作用的实验研究．江苏中医药，2002，23：39-40
51. Wang LT. Zhang B, Chen JJ. Effect of anti-fibrosis compound on collagen expression of hepatic cells in experimenlal liver fibrosis of rats. World J Gastroenterol, 2000, 6: 877-880
52. Bruck R. Shirin H, Aeed H. et al. Prevention of hepatic cirrhosis in rats by??hydroxyl radical scavengers. J Hepatology, 2001, 35: 457-464
53. Xu JW, Gong J, Chang XM, et al. Effects of estradiol on type Ⅰ, Ⅲ collagens and TGF β_1 in hepatic fibrosis in rats. Shijie Huaren Xiaohua Zazhi 2003; 11: 1185-1188.
54. Ozenirler S, Dincer S, Akyol G, et al. The protective effect of Ginkgo biloba extract on CCl_4-induced hepatic damage. Acta Physiol Hung. 1997-98; 85 (3) : 277-85.
55. Okazaki I, Watanabe T, Hozawa S, et al. Molecular mechanism of reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinase. J Gastroenterol Hepatol. 2000; 15 Suppl; D26-32
56. Carcia Trevijano ER, Iraburu MJ, Fontana L, et al. Transforming growth factor betal induces the expression of alpha(r) procollagen mRNA by a hydrogen peroxide C/EBP beta dependent mechanism in rat hepatic stellate cells. Hepatology. 1999; 29 (3) : 960-970.
57. Yao XX, Tang YW, Yao DM, et al. Effects of Yigan Decoction on proliferation and apoptosis of hepatic stellate cells. World J Gastroenterol, 2002, 8: 511-514
58. Wadsworth TL, McDonald TL, Koop DR. Effect of Ginkgo biloba extract(EGb761) and quercetin on lipopolysaccharide-induced signaling pathways involved in the release of tumor mecrosis factor-α. Biochem Phanna, 2001, 62: 963-974
59. Bridi R, Crossetti FP, Steffen VM, et al. The antioxidant activity of standardized extract of ginkgo biloba(EGb761)in rats. Phytother Res, 2001, 15: 449-451
60. Gohil K. Packer L. Bioflavonoid-rich botanical extracts show antioxidant and gene regulatory, activity. Ann N y Acad Sci, 2002, 957: 70-77
61. Smith JV, Luo Y. Studies on molecular mechanisms of Ginkgo biloba extract. Appl Microbiol Biotechnol. 2004, 64 (4) : 465-72.
62. Kitade Y. Watanabe S, Masaki T. et al. Inhibition of liver fibrosis in LEC rats by a carotenoid, lycopene, or a herbal medicine. Sho-Saiko-to. Hepatology Res, 2002. 22: 196-205
63. Friedman SL. Molecular regulation and hepatic fibrosis, an integrate cellular??response to tissue injure. J Biol Chem2000; 275: 2247-2250.
64. Hock JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002; 27: 63-68.
65. Albanis E, Friedman SL. Hepatic fibrosis: Pathogenesis and priciples of therapy. Clin Liver Dis, 2001, 5 (2) : 315-334.
66. Lamireau T, Desmouliere A, Bioulac-Sage P, et al. Machanisam of hepatic fibrogenesis. Arch Pediatr, 2002, 9 (4) : 392-405.
67. Kanzler S, Lohse AW, Keil A, et al. TGF-beta 1 in liver fibrosis: an inducible transgenic mouse model to study liver fibrogenesis. Am J Physiol, 1999, 27 (4) : 1059-1068.
68. Wang XZ, Zhang LJ, Li D, et al. Effects of transmitters and interleukin-10 on rat hepatic fibrosis induced by CCl4. World J Gastroenterol, 2003, 9: 539-543.
69. Friedman SL. Molecular regulation of hepatic fibrosis, an integrate cellular response to tissue injure. J Biol Chem. 2000, 275: 2247-2250.
70. Teresa K, Woodruff. Regulation of cell and system function by Activin. Biochemical Pharmacology. 1998, 55: 953-963.
71. Okuno M, Akita K, Moriwaki H, et al. Prevention of rat hepatic fibrosis by the protease inhibitor, camostat mesilate, via reduced generation of active TGF-beta. Gastroenterology 2001; 120: 1784-1800
72. Gentilini A, Feliers D, Pinzani M, et al. Characterization and regulation of insulin like growth factor binding proteins in human hepatic stellate cells. J Cell Physiol. 1998; 174 (2) : 240-250.
73. Roberts RA, James NH, Cosulich SC. Therole of protein kinase mitogen activated protein kinase in epidermal growth factor and tumor necrosis factor alpha mediated rat hepatocyte survival and apoptosis, Hepatology. 2000; 31 (2) : 420-427.
74. Kim KY, Choi T, Kim SS. Progression of hepatic stellate cell activation is associated with the level of oxidative stress rather than cytokines during CCl_4-induced fibrogenesis. Mol Cell. 2000; 10 (3) : 289-300
75. Lee KS, Lee SJ, Park HJ. et al. Oxidative stress effect on the activation of hepatic??stellate cells. Yonsei Med J. 2001; 42 (1) : 1-8
76. Rockey DC. The cell and molecular biology of hepatic fibrogensis: clinical and therapeutic implications. Clin Liver Dis. 2000; 4: 319-355
77. Schwabe RF, Schnabl B, Kweon YO, et al. CD40 activates NF-kappa B and c-JunN-terminal kinase and enhances chemokine secretion on activated human hepatic stellate cells. J Immunol. 2001; 166 (11) : 6812-6819
78. De-Blesser PJ, Niki T, Rogiers V, et al. Apoptosis of hepatic stellate cells: involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 2001; 48: 548-557
79. Greenwel P, Dominguez-Rosales JA, Mavi G, et al. Hydrogen peroxide: a link between acetaldehyde-elicited alphal(Ⅰ) collagen gene up-regulation and oxidative stress in mouse hepatic stellate cells. Hepatology. 2000; 31: 109-116
80. Sato M, Kakubari M, Kawamura M, et al. The decrease in total collagen fibers in the liver by hepatocyte growth factor after formation of cirrhosis induced by thioacetamide. Biochem Pharmacol. 2000; 59 (6) : 681-90
81. Baroni GS, Pastorelli A, Manzin A, et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver. 1999 Jun; 19 (3) : 212-219.
82. Murawaki Y, Nishimura Y, lkuta Y, et al. Plasma transforming growth factor betal concentrations in patients with chronic viral hepatitis. J Gastroenterol Hepatol. 1998; 13 (7): 680-684.
83．甘雪婷，白宪光．细胞因子TGF-β与慢性肝病肝纤维化的关系．医学信息．2002；15(7)：466-468
84. Albanis E. Friedman SL. Hepatic fibrosis. Pathogenesis and principles of therapy. Clin Liver Dis. 2001; 5: 315-334
85. Luisi S, Florio P, Reis FM. et al. Expression and secretion of activin A: possible physiological and clinical implications. Eur J Endocrinol. 2001, 14 5(3) : 225-236.
86. Naumnik B, Borawski J. Mysliwiec M. Activin A-follistatin: new cytokines, new perspectives. Pol Arch Med Wewn. 2003. 109 (4) : 431-435.
87. Patella S, Phillips DJ, Kretser DM, et al. Characterization of serum activin A and??0follistation and their relation to virological and histological determination in chronic virtual hepatitis. J Hepatol 2001;34:576-583.
88. Pirisi M, Fabris C, Luisi S, et al. Evaluation of circulating activinA as a serum marker of hepatocelluar carcinoma. Cancer Detect Prev 2000, 24:150-155.
89. Wagner K, Peters M, Scholz A, et al. Activin A stimulates vascular endothelial growth factor gene transcription in human hepatocellular carcinoma cells. Gastroenterology. 2004,126(7):1828-1843.
90. Huang X, Li DG, Wang ZR,et al. Expression changes of activin A in the development of hepatic fibrosis. World J Gastroenterol. 2001,7(l):37-41.
91. Sugiyama M, Ichida T, Sato T, et al. Expression of activin A is increased in cirrhotic and fibrotic rat livers. Gastroenterology, 1998;114:550-558.
92. Gold EJ, Francis RJ, Zimmermann A, et al. Changes in activin and activin receptor subunit expression in rat liver during the development of CCM-induced cirrhosis. Mol Cell Endocrinol. 2003 , 28:201 (1-2): 143 -153.
93. Date M, Matsuzaki K, Matsushita M, et al. Differential regulation of activin A for hepatocyte growth and fibronectin synthesis in rat liver injury. J Hepatol. 2000,32(2):251-260.
94. Hughes RD. Evans LW. Activin A and follistatin in acute liver failure. Eur J Gastroenterol Hepatol. 2003,15(2):127-131
95. Ohnishi N, Miyata T, Ohnishi H, et al. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut. 2003,52(10): 1487-1493.
96. Wada W, Kuwano H, Hasegawa Y, et al. The dependence of transforming growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology. 2004,145(6): 2753-2759..
97. Gold EJ. Francis RJ. Zimmermann A, et al. Changes in activin and activin receptor subunit expression in rat liver during the development of CCM-induced cirrhosis. Mol Cell Endocrinol. 2003 ,28:201(1-2): 143-153.
98. Yasuda H, Mine T, Shibata H, et al. Activin A: an autocrine inhibitor of initiation of DNA synthesis in rat hepatocytes. J Clin Invest. 1993.92(3): 1491-1496.99. Hully JR, Chang L, Schwall RH, et al. Induction of apoptosis in the murine liver with recombinant human activin A. Hepatology. 1994,20(4 Pt 1):854-862.
100. Kanamaru C, Yasuda H, Fujita T. Involvement of Smad proteins in TGF-beta and activin A-induced apoptosis and growth inhibition of liver cells. Hepatol Res. 2002,23(3):211-219.
101. Ichikawa T, Zhang YQ, Kogure K, et al. Transforming growth factor beta and activin tonically inhibit DNA synthesis in the rat liver. Hepatology. 2001;34(5):918-925.
102. Gold EJ, Zhang X, Wheatley AM, et al. betaA- and betaC-activin, follistatin, activin receptor mRNA and betaC-activin peptide expression during rat liver regeneration. J Mol Endocrinol. 2005,34(2):505-515.
103. Wada W, Kuwano H, Hasegawa Y, et al. The dependence of transfonning growth factor-beta-induced collagen production on autocrine factor activin A in hepatic stellate cells. Endocrinology. 2004,145(6):2753-2759.
104. Ohnishi N, Miyata T, Ohnishi H, et al. Activin A is an autocrine activator of rat pancreatic stellate cells: potential therapeutic role of follistatin for pancreatic fibrosis. Gut. 2003,52(10): 1487-1493.
105. Breitkopf K, Lahme B, Tag CG, et al. Expression and matrix deposition of latent transforming growth factor beta binding proteins in normal and fibrotic rat liver and transdifferentiating hepatic stellate cells in culture. Hepatology 2001; 33: 387-396
106. Britton RS, Bacon BR. lntracellular signsling pathways in stellate cell activation. lsr Med Assone J ,2000,2(sUPPL):7480.
107. Tanigucbi H, Kato N, Otsuka M. et al. Hepatitis C virus core protein upregulate transforming growth factor-beta 1 transcription. J Med Virol, 2004, 72(1): 52-59.
108. Yang C, Zeisberg M. Mosterman B, et al. Liver fibrosis: insights into migration of hepatic stellate cells in response to extracellular matrix and growth factors. Gastroenterology, 2003.24(2):147-159.
109. Wang JY, Zhang QS, Guo JS. et al. Effects of glycyrrhetinic acid on collagen metabolism of hepatic stellate cells at different stages of liver fibrosis in rats.??World J Gastroenterol, 2001, 7:115-119
110. Gagliano N, Arosio B, Grizzi F, et al. Reduced collagenolytic activity of MMPs and development of liver fibrosis in the aging rat. Machan Aging Develop, 2002, 123:413-425
111. Murphy FR, Issa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by tissue inhibitor of metalloproteinase-1 is mediated via effects of matrix metalloproteinase inhibition: implications for reversibility of liver fibrosis. J Biol Chem, 2002, 277: 11069-11076
112. Bruck R, Shirin H, Aeed H, et al. Prevention of hepatic cirrhosis in rats by hydroxyl radical scavengers. J Hepatol, 2001, 35: 457-464
113. Parola M, Robine C. Oxidative stress-related molecules and liver fibrosis. J Hepatol, 2001, 35:297-306
114. Reeves HL, Dack CL, Peak M, et al. Stress-activated protein kinases in the activation of rat hepatic stellate cells in culture. J Hepatol, 2000; 32:465-472
115. Chen W, Woodruff TK, Mayo KE. Activin A-induced HepG2 liver cell apoptosis: involvement of activin receptors and smad proteins. Endocrinology, 2000, 141: 1263-1272
116. Hoek JB, Pastorino JG. Ethanol, oxidative stress, and cytokine-induced liver cell injury. Alcohol. 2002; 27: 63-68.
117. Aibanis E, Friedman SL. Hepatic fibrosis: Pathogenesis and priciples of therapy. Clin Liver Dis, 20015(2):315-334.
118．王爱民，杨晓明，王文犀，等．重组人肝再生增强因子抑制实验性肝纤维化MMP-2基因表达．中华消化杂志，2002，22：29229-4
119．谢彦华，李里，王立娥，等．MMP-2、-9与肝纤维化．临床肝胆病杂志，2002，11：82-84
120. Gardi C. Arezzini B, Fortino V, et al. Effect of flee iron on collagen synthesis, cell proliferation and MMP-2 expression in rat hepatic stellate cells. Biochem Pharmacol. 2002, 64: 1139-1145
121. Boeker KH. Haberkorn Cl, Michels D, et al. Diagnostic potential of circulating TIMP-1 and MMP-2 as markers of liver fibrosis in patients with chronic hepatitis??C. Clin China Acta, 2002, 316:71-81
122. Okazaki I, Watanabe T, Hozawa S, et al. Molecular mechanism of the reversibility of hepatic fibrosis: with special reference to the role of matrix metalloproteinases. J Gastroenterology Hepatology, 2000, 15 (suppl): D26-D32
123. Michael JR Fibrogenesis Ⅱ. Metalloproteinases and their inhibitors in liver fibrosis. AJP-Gastrointestinal Liver Physiology, 2000, 279: G245-G249,
124. Guo MZ, Li XS, Xu HR, et al. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin, 2002, 23:739-744
125. Wang JY, Guo JS, Yang CQ. Expression of exogenous rat collagenase in vitro and in a rat model of liver fibrosis. World J Gastroenterol, 2002, 8:901-907
126. Iredale JP, Benyon RC, Pickering J, et al. Mechanisms of spontaneous resolution of rat liver fibrosis; hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors. J Clin Invest, 2001, 102:538-549
127. Ninomiya T, Yoon S, Nagano H, et al. Significance of serum matrix metalloproteinases and their inhibitors on the antifibrogenetic effect of interferon-alfa in chronic hepatitis C patients, Intervirology, 2001, 44: 227-231
128. Liu P, Hu YY, Liu C, et al. Clinical observation of salvianolic acid B in treatment of liver fibrosis in chronic hepatitis B. World J Gastroenterol, 2002, 8: 679-685
129. Murply HR, lssa R, Zhou X, et al. Inhibition of apoptosis of activated hepatic stellate cells by TIMP-2 is mediated via effects on MMP inhibition: implications for reversibility of live fibrosis. J Biol Chem, 2002, 277: 11069-11076
130. Weng HL. Cai WM, Liu RH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis. World J Gastroenterol. 2001, 7:42-48
131. Yoshiji H, Kuriyama S, Miyamoto Y. et a1. TIMP-1 promotes liver fibrosis development in a transgenic mouse model. Hepatology, 2000, 32: 1248-1254
132．杨长青，胡国龄，谭千德，等．实验性肝纤维化时MMP-1、TIMP-1的表达与Ⅰ、Ⅲ型肢原含量变化的关系．临床肝胆病杂志，2000，16：222-224
133. Nie QH. Cheng YQ, Xie YM. et al. Methodologic research on TIMP-1. TIMP-2 detection as a new diagnostic index for hepatic fibrosis and its significance. World J Gastroenterol, 2002. 8: 282-287134. Nie QH, Cheng YQ, Xie YM, et al. Inhibiting effect of antisense oligonucleotides phosphorthioate on gene expression of TIMP-1 in rat liver fibrosis. World J Gastroenterol, 2001, 7:363-369
135. Liu WB, Yang CQ, Jiang W, et al. Inhibition on the production of collagen type Ⅰ, Ⅲ of activated hepatic stellate cells by antisense TIMP-1 recombinant plasmid. World J Gastroenterol, 2003, 9:316-319
136. Liu HL, Li XH, Wang DY, et al. Matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-1 expression in fibrotic rat liver. World J Gastroenterol, 2000, 6:881-884
137. Guo MZ, Li XS, Xu HR, et al. Rhein inhibits liver fibrosis induced by carbon tetrachloride in rats. Acta Pharmacol Sin, 2002, 23:739-744
138. Williams EJ, Benyon RC, Trim N, et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut, 2001,49:577-5831．程明亮，杨长青．肝纤维化的基础研究及临床．北京，人民卫生出版社，2002：2～20
2．梁扩寰，李绍白．肝脏病学．北京，人民卫生出版社，1995
3. Ozenirler S, Dincer S, Akyol G. et al. The protective effect on Ginko binka extract on CCL~4-induced hepatic damage. Area Physiol Hung. 1997-89;85(3):277-85
4. Czaja MJ, Weiner FR. Flanders KC, et al. In vitro and in vivo association of Teansforming Growth Factor-1 with hepatic fibrosis. J Cell Biology. 1989. 108(6): 2477-2482
5．宋仕玲．细胞因子及其网络对肝纤维化的作用．人民军医，200 3，46(10)：606-609
6. ]Lau AL. Kumar TR, Nishimor K. et al. Activin beta C and beta E genes are not??essential for mouse liver growth differentiation, and regeneration. Mo; Cell Biol, 2000,20:6127-6137
7. Date M, Matsuzaki K, Matsushita M, et al. Differential regulation of activinA for hepaticyte growth and fibronectin synthesis in rat liver injuty. J H epatol, 2000.32:251-260
8. Patella S, Phillips DJ, Kretser DM, et al. Characterixation of serum activinA and follistation and their relation to virological and histological determination in chronic virtual hepatitis. J Hepatol 2001;34:576-583
9. Harada K, Shintani Y, Wakatsuki M, et al. Serum immunoreactive activin A in normal subjects and patients with various diseases. J Cli Endoctino Metab 1996;81:2125-2130
10. Pisisi M, Fabris C, Luisi S, et al. Evaluation of circulating activinA as a serum marker of heptocellular carcinoma. Cancer Detect Prev 2000;24:150-155
11．黄新，李定国．激活素及相关肽与肝脏疾病研究进展．中华肝脏病杂志，2000，8(5)：319-320
12. Yasuda H, Mine T, Shibata H, et al. Activin A: an autocrine in hibitor of initiation of DNA synthesis in rat hepatocyres[J], J. Clin Invest. 1993,92(9):1491-1496
13. Schwall RH, Robbins K, Jardieu P, et al. Activin A induces cell drath in hepatocytes invivoand in vitro [J]. Hepatology, 1993,18(2):347-356
14. Hully JR, Chang L, Schwall RH, et al, Induction of apoptosis in the murine liver recombinant human activin A[J]. Hepatology, 1994,20(4):854-862
15. Zhang YQ, Kanzaoi M, Mashima H. et al. Norepinephrine reverses the effects of activin A on DNA synthesis and apoptosis in cultured rat hepatocytes[J]. Hepatology, 1996, 23(2):288-293.
16. Gaca MD. Pickering JA. Arthur MJ et al. Human and rat hepatjc stellate cells produce ste m cell factor: a possible mechanis m for mast sell recruit in liver fibrosis. J Hepatol,1999,30(5):850
17．卢良威．肝纤维化的治疗研究．浙江中医学院学报，2001，25(2)：25-27
18. Riveta CA. Bradford BC, Hunt KJ. et al. [J]. Am J Physol Gastrointest Liver Physiol. 2001Jul. 281(1): G 200-G20719. Kim KY, Choi T, Kim SS. [J]. Mol Cells, 2000 Jun 30, 10(3): 289-300
20. Albanis E, Friedman SL. [J]. Clin Liver Dis, 2001, 5(2): 315-34
21. Zhu N, Ramirez LM, Lee RL, et al. [J].J Immunol 2002; 168:744-754
22. Lee KS, Lee SJ, Park HJ, et al. [J]. Yonsei Mde J, 2001 Feb, 42(1): 1-8
23. Rockey DC, Fouassier L, Chung JJ, et al. [J]. Hepatology, 1998,27:472 480.
24. Hellerbrand C, Stefanovic B, Ciordano F. [J]. J Hepatol, 1999, 30(1): 77-87
25. Okuno M, Akita K, Moriwake H, et al. [J]. Gastoenterology, 2001 Jun, 120(7): 784-800
26. George J, Roulot D, Koteliansky VE, et al. [J].Proc Natl Acad Sci USA, 1999 Oct 26,96(22): 19-24
27. Nakathura T, Sakata R, Ueno T, et al. [J]. Hepatology, 2000Aug, 32(2): 247-255
28. Swaisgood CM, French EL, Noga C, et al .[J]. Am J Pathol, 2000,157:177-187
29. Sato M. Kawanmura M, Kakubari M, et al. [J]. Biochem Pharmacol, 2000 Mar 15, 59(6): 681-90
30. Bruck R, Genina O, Aeed H, et al. [J]. Hepatology, 2001 Feb, 33(2): 379-86
31. Kimura K. Ando K, Ohnishi H, et al. [J]. Int immunol, 1999, 119:1491-500
32. Okuyama H, Shimahara Y, Kawada N, et al. [J]. J Biol Chem. 2001 Jul 27, 276
33. Gaca MD. Pickering JA. Arthur MJ et al. Human and rat hepatic stellate cells produce ste m cell factor: a possible mechanism for mast sell recruit in liver fibrosis. J Hepalol,1999,30(5):850
34. Okuyama H, Shimahara Y. Kawada N. et al. [J]. J Biol Chem. 2001 Jul 27,276
35. Schwall RH, Robbins K, Jardieu P. et al. Activin A induces cell drath in hepatocytes invivoand in vitro [J]. Hepatology, 1993.18(2):347-356
36. Hully JR, Chang L, Schwall RH. et al. Induction of apoptosis in the murine liver recombinant human activin A [J]. Hepatology. 1994.20 (4): 854-862
37. Zhang YQ, Kanzaoi M. Mashima H. et al. Norepinephrine reverses the effects of activin A on DNA synthesis and apoptosis in cultured rat hepatocytes [J]. Hepatology, 1996,23(2):288-293.1. Bcnyon RC Arther M J[J]. J Pcdiatr Gastrocn-terol Nutr,1998 27(1): 75-85
2. Zhong Z, Froh M, Whcclcr MD, et al [J]. Gene Thcr, 2002,9,183-191
3. Rivcta CA, Bradford BC, Hunt KJ, et al[J] Am J Physol Gastrointest Livcr Physiol, 2001,281(1):G200-G207
4. Kim KY, Choi T, Kim SS[J]. Mol Cells, 2000,10(3): 289-300
5. AlSanis F, Fricdman SL[J]. Clin Livcr Dis ,2001,5 (2): 315-334
6. Zhu N, Ram irEz LM, Lee RL, et al [J]. Jlnmunol,2002,168:744-754
7. Lee KS, Lee SJ, Pack H J, et al[J]. Yonsci Mcdl, 2001,42(1): 1-8
8. Rockey DC, Fouassicr L, Chung JJ, et al[J], Hepatology,1998, 27:472-480
9. Wu J. EmS IA[J]. J Gastroenterol, 2000,35(9): 665-762
10. Hellerbrand C, Stefanovic B, Ciordano F. [J]. J Hepatol, 1999, 30(1): 77-87
11. Benedetti A, Di Sario, Casini A, et al[J], Gastroenterology; 2001, 120(2): 545-556
12. Okuno M, Akita K, Moriwake H, et al. [J]. Gastoenterology, 2001 Jun, 120(7): 784-800
13. George J, Roulot D, Koteliansky VE, et al. [J].Proc Natl Acad Sci USA, 1999 Oct 26,96(22): 19-24
14. Nakathura T, Sakata R, Ueno T, et al. [J]. Hepatology, 2000Aug, 32(2): 247-255
15. Benedetti A. Di Sario, Casini A, et al[J], Gastroenterology; 2000. 120(2): 545-556
16. Fischer R. Schm itt M, Bodc JG. et al[J], Gastroenterology, 2001. 120(5):1212-1226
17. Swaisgood CM. French EL, Noga C. et al .[J]. Am J Pathol. 2000.157:177-187
18. Sato M, Kawanmura M, Kakubari M. et al. [J]. Biochem Pharmacol. 2000 Mar 15.59(6): 681-90
19. Bruck R. Genina O. Aeed H. et al. [J]. Hepatology. 2001 Feb. 33(2): 379-86
20. [2o] Kimura K. Ando K. Ohnishi H, et al. [J]. Int immunol, 1999. 119:1491-50021. Okuyama H, Shimahara Y, Kawada N, et al. [J]. J Biol Chem, 2001 Jul 27, 276
22. Iredale JP, Bebyon RC, Pickering J. et al[J]. Clin Invest, 1998,102(3): 538-549
23. Re rolle JP, Hertig A, Nguyen G, et al. [J]. Kidney Int, 2000,1841-1850
24. Salgado S, Garcia J, Vera J, et al. [J]. Mol Ther, 2000,2,545-551
25. Park PH, Nan JX, Fark EJ, et al. [J]. Phamacol Toxicol, 2000,87(8): 261-268
26. Kitade Y, Watanabe S, Masaki T, et al, [J], Henatol Res,2002,22(3): 196-205
27. Gohil K, Pacher L, [J]. Ann NY Acad Sci, 2002,95(7):70-77
28. Dem irdag K, Bahcecioglu IH, Ozerean IH, et al. [J]. J Gastroenterol Hepatol, 2004,19(3): 333-338
29. Okazaki T, Watanabe T, Hozawa S, et al.[J].Keil J Med,2001,50(2):58-65
30. Rutao C, Baoen W, Fukui Z, et al. [J]. Chin Med J, 2003,116(3):378-38215．胡义扬，刘平，刘成，等，丹酚酸A抗四氯化碳中毒致大鼠肝损伤和肝纤维化的作用[J]，中国药理学报，1997，18(5)：478-480
16．胡义杨，刘成，刘平，中药有效成分抗肝纤维化研究现状与展望[J]，中草药，1996，27(3)：183-186
17．陈岳祥，李石，范列英等，丹参单体IH764-3抗肝纤维化作用的实验研究，中华医学杂志，1998，8(8)：636-637
18．周俭平，张俊平，刘福党，等，植物黄酮对成纤维细胞增殖和胶原合成的影响[J]，中国药学杂志，1999；34(10)：668-669
19．时昭红，张介眉等，银杏叶提取物对实验性大鼠肝纤维化的逆转作用，中国中西医结合消化杂志，2005，13(3)：148-152
20．曹献英，贲长恩，于世瀛，等．活血化瘀方药抗肝纤维化的形态学研究[J]．武汉大学学报(医学版)，2001，22(1)：37
21．吴亚云，程明亮，陆彤，等．汉丹肝乐对大鼠肝贮脂细胞增殖的影响[J]．贵州医药，2000，24(1)：15
22．杨玲，朱清静，张赤志．抗纤软肝冲剂药物血清对激活肝星状细胞表达Ⅰ型前胶原及TGF-BlmRNA的影响[J]．中国中医基础医学杂志，2001，7(8)：38
23．周小舟，周人桥，漆艳平，等．软肝冲剂对四氯化碳肝硬化大鼠P21mRNA表达的影响[J]．湖南中医学院学报，2002，22(4)：13
24．王灵台，张斌，陈建杰，等．抗纤复方药物血清对肝纤维化大鼠肝细胞生成胶原的影响[J]．中华消化杂志，1999，19(6)：391
25．丁惠国，赵春惠，唐淑珍，等．复方861对肝星状细胞分泌表达内皮素-1蛋白及mRNA的影响[J]．中华肝脏病杂志，2003，11(5)：308
26．刘成海，王晓玲，刘平，等．扶正化瘀319方药物血清对肝星状细胞型胶原及转化生长因子B-1表达的影响[J]．中国中西医结合杂志，1999，19(7)：412
27．郭晓萍，侯允天，李东良，等．柔肝煎冲剂对实验性肝纤维化大鼠血清透明质酸及型前胶原的影响[J]．中医药学报，1996，12(5)：42
28．杨国汉，戴裕光，钟瑜．肝结散抗肝纤维化治疗中PCⅢ、HA、LN的动态变化[J]．北京中医药大学学报，2003，26(1)：4229．许亦斌，季光，曹承楼，等，清肝活血方对肝星状细胞增殖及胶原生成的影响[J]．实用临床医药杂志，2003，7(3)：243
30．朱清静，杨玲．剔毒护肝方对肝星状细胞表达型胶原及TGFβ-1mRNA的影响[J]．中国中医药科技，2002，9(2)：76
31．褚裕义，孙克伟，刘伟士，等．疏肝理脾片抗大鼠免疫性肝纤维化研究[J]．中国中西医结合脾胃杂志，1998，6(2)：98
32．龙爱华，王树槐，陈瑾，等．抑肝健脾复方对肝纤维化大鼠HA、PCⅢ、Ⅳ-C、HyP的影响[J]．中国实验方剂学杂志，2000，6(6)：30
33．田玉岭，刘新钰，张林，等．丹参定位注射抗肝纤维化的临床研究，中西医结合肝病杂志，1998，8(2)：107-8
34．高荣慧．神阙穴敷灸治疗早期肝硬化的临床观察．中国针灸，1996，9：25-6